{
    "nctId": "NCT02872064",
    "briefTitle": "Treatment of Primary Breast Cancer Using PDT",
    "officialTitle": "A Phase I/IIa, Open Label, Single Site Light Dose Escalation Trial of Single Dose Verteporfin Photodynamic Therapy (PDT) in Primary Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 12,
    "primaryOutcomeMeasure": "Establish the minimum effective light dose",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients aged 30 or over\n2. A uni-focal invasive ductal breast carcinoma or discrete uni-focal site which is deemed suitable for PDT within a multifocal invasive ductal carcinoma in a single breast.\n3. Patients who have opted for mastectomy or wide local excision as primary treatment.\n4. Capable of giving written informed consent\n\nExclusion Criteria:\n\n1. Patients who are not undergoing surgery as their primary treatment.\n2. Patients undergoing surgery for DCIS without invasive breast cancer.\n3. Patients with Lobular cancer\n4. Patients with Necrotic tumours\n5. Distant metastatic disease.\n6. Patients will be excluded if they have porphyria or are sensitive to verteporfin (visudyne).\n7. Patients who have severe cardiovascular disease.\n8. Patients with severe or uncontrolled systemic disease e.g. hepatic impairment.\n9. Patients with laboratory findings that make it undesirable for the patient to participate in the trial.\n10. Male breast cancer patients\n11. Pregnancy and lactation.\n12. No patients with any psychiatric disorder making reliable informed consent impossible.\n13. Patients will be excluded if taking part in any other trial of an experimental medicine\n14. Patients will be excluded if taking endocrine therapy drugs that could confound the results.",
    "sex": "FEMALE",
    "minimumAge": "30 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}